Ligand Pharma (LGND) Tops Q2 EPS by 29c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $262.17 --0%
EPS Growth %: +25.6%
Financial Fact:
Research and development: 5.9M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: +25.6%
Financial Fact:
Research and development: 5.9M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.63, $0.29 better than the analyst estimate of $1.34. Revenue for the quarter came in at $54.7 million versus the consensus estimate of $70.41 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- Prosperity Bancshares (PB) Reiterated at Overweight by Cantor Fitzgerald as Estimates Revised
- Bristow Group to acquire Berry Aviation for $105 million
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
